Paper Details

  1. Home
  2. Paper Details

Predictors of Topical Use in Psoriasis Patients in the REFINE Study.

Author: BayanNabil, GooderhamMelinda J, PappKim A, Poulin-CostelloMelanie, SheltonJennifer

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Patients with moderate to severe plaque psoriasis receiving etanercept who did not achieve a PASI 90 at week 12 were more likely to use topical agents, particularly high-potency agents.
Paper Details　
Original Abstract of the Article :
BACKGROUND: The factors influencing the use of topical agents in combination with biologic therapies for the treatment of plaque psoriasis (PsO) are not well understood. OBJECTIVE: To examine potential predictors of topical use in patients with moderate to severe plaque PsO receiving etanercept (ET...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1177/1203475415604322

データ提供：米国国立医学図書館（NLM）

Topical Treatment for Psoriasis: Factors Influencing Patient Choice

Psoriasis is a chronic skin condition that can be challenging to manage. This study explores the factors influencing the use of topical agents in combination with biologic therapies for the treatment of plaque psoriasis. The researchers analyzed data from the REFINE study, focusing on patients receiving etanercept (ETN) treatment.

The study found that achieving a PASI 90 response at week 12 was a significant predictor of whether patients would use topical agents. Patients who did not achieve this response were more likely to use topical agents, particularly those with high potency.

Topical Treatment: A Tailored Approach for Psoriasis Management

This study provides insights into the factors influencing patient choice regarding topical treatment for psoriasis. The research suggests that achieving a PASI 90 response at week 12 is a key factor in determining the need for topical agents, particularly those with high potency.

Dr. Camel's Conclusion

This study offers valuable information for clinicians treating patients with psoriasis. It highlights the importance of considering individual patient needs and responses to treatment when making decisions about topical therapies. Tailoring treatment plans to individual needs is crucial for optimal outcomes.

Date :
  1. Date Completed 2016-05-10
  2. Date Revised 2016-02-18
Further Info :

Pubmed ID

26330052

DOI: Digital Object Identifier

10.1177/1203475415604322

Related Literature

Article Analysis
・Effective treatment of psoriasis
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.